Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
| Title: | Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis. |
|---|---|
| Authors: | Mohamed Ali Elbashir R; General Practice, Barnsley Hospital NHS Foundation Trust, Barnsley, GBR.; Elbashir A; Department of Medicine, Barnsley District General Hospital, Barnsley, GBR.; Urimuke Basake R; Department of Acute Medicine, Aberdeen Royal Infirmary, Aberdeen, GBR.; Zakaria Ahmed Mohieldin A; Department of Medicine, Ahfad University for Women, Omdurman, SDN.; I A Elhaj N; Pediatric Department, Royal Edinburgh Hospital, Edinburgh, GBR.; Ebrahim Mohamed Ebrahim F; Emergency Medicine, SABA Clinic, Jeddah, SAU.; Gase Ahmed W; Department of Medicine, Ahfad University for Women, Omdurman, SDN.; Abdelrahim Mohamed Mahgoub O; Department of Medicine, University of Khartoum, Khartoum, SDN. |
| Source: | Cureus [Cureus] 2025 Nov 02; Vol. 17 (11), pp. e95938. Date of Electronic Publication: 2025 Nov 02 (Print Publication: 2025). |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Palo Alto, CA : Cureus, Inc. |
| Abstract: | Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) treat overweight or obesity with or without diabetes. This review aims to evaluate the effects of GLP-1 RAs on weight and cardiometabolic measures. This systematic review and meta-analysis of randomized trials from PubMed, Scopus, Web of Science, and Embase followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Two reviewers extracted the data and assessed the quality with the Cochrane Risk of Bias 2 (RoB 2) tool. Thirteen randomized controlled trials were included. We concluded that GLP-1 RAs reduced mean percentage body weight by -12.79% (95% CI: -15.12 to -10.46), BMI by -4.80 kg/m² (95% CI: -6.24 to -3.36), waist circumference by -9.78 cm (95% CI: -11.47 to -8.09), systolic blood pressure (BP) by -6.32 mmHg (95% CI: -7.92 to -4.72), and diastolic BP by -1.95 mmHg (95% CI: -3.21 to -0.69). Risk ratios for ≥5%, ≥10%, ≥15%, and ≥20% weight loss were 2.98, 5.56, 9.50, and 15.00, respectively. Tirzepatide showed greater reductions than semaglutide. GLP-1 RAs, particularly tirzepatide, achieve substantial weight loss and improve cardiometabolic risk factors.; (Copyright © 2025, Mohamed Ali Elbashir et al.) |
| Competing Interests: | Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. |
| References: | Nat Med. 2023 Nov;29(11):2909-2918. (PMID: 37840095); Diabetes Care. 2025 Feb 01;48(2):292-300. (PMID: 39841962); N Engl J Med. 2023 Dec 14;389(24):2221-2232. (PMID: 37952131); Nature. 2006 Dec 14;444(7121):881-7. (PMID: 17167477); Obesity (Silver Spring). 2015 Jun;23(6):1119-29. (PMID: 25959380); JAMA. 2024 Aug 20;332(7):551-560. (PMID: 38819983); N Engl J Med. 2016 Jul 28;375(4):311-22. (PMID: 27295427); N Engl J Med. 2021 Mar 18;384(11):989-1002. (PMID: 33567185); JAMA. 2021 Apr 13;325(14):1403-1413. (PMID: 33625476); Am J Cardiovasc Drugs. 2025 Jul;25(4):491-518. (PMID: 40246808); Lancet Diabetes Endocrinol. 2024 Sep;12(9):631-642. (PMID: 39089293); Horm Metab Res. 2022 Jul;54(7):458-471. (PMID: 35512849); Lancet Diabetes Endocrinol. 2025 Oct;13(10):838-847. (PMID: 40825340); N Engl J Med. 2022 Jul 21;387(3):205-216. (PMID: 35658024); Lancet Diabetes Endocrinol. 2025 May;13(5):384-396. (PMID: 40031941); Nat Med. 2022 Oct;28(10):2083-2091. (PMID: 36216945); Int J Obes (Lond). 2014 Jun;38(6):784-93. (PMID: 23999198); Nat Med. 2025 Jan;31(1):278-285. (PMID: 39455729); Diabetes Obes Metab. 2024 Mar;26(3):1057-1068. (PMID: 38105342); Lancet. 2023 Aug 26;402(10403):705-719. (PMID: 37385278); N Engl J Med. 2025 Jul 3;393(1):26-36. (PMID: 40353578); Diabetologia. 2024 Jul;67(7):1206-1222. (PMID: 38613667) |
| Contributed Indexing: | Keywords: diabetes; diabetes type 2; glp-1 receptor agonists; type 1 diabetes mellitus; weight reduction |
| Entry Date(s): | Date Created: 20251204 Date Completed: 20251204 Latest Revision: 20251206 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12670982 |
| DOI: | 10.7759/cureus.95938 |
| PMID: | 41341350 |
| Database: | MEDLINE |
Journal Article; Review